30 closest matches · ranked by relevance
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Polycystic Ovary Syndrome
Primary: Estradiol During Phase I and Phase II — 451.7; 116; 247.2; 131.4 pmol/L
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Ovarian Cancer
Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Ovarian Cancer
Primary: Efficacy Patient Level — 26.9 percentage of participants
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Adult Type Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma · Ovarian Sertoli-Leydig Cell Tumor
Primary: Probability of Complete Clinical Response — 3.2 Percentage of Participants
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 0; 0 participants
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Carcinoma
Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Recurrent Extragonadal Seminoma · Recurrent Malignant Extragonadal Germ Cell Tumor · Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
Primary: Objective Response Rate — 0; 6; 2; 10 participants
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Ovarian Clear Cell Carcinoma
Primary: Six Month Progression Free Survival Rate — 8 Participants
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Ovarian Cancer
Primary: PFS — 29.8 Months
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)